华森制药(002907) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the period reached CNY 221,121,082.21, a year-on-year increase of 22.21%[9] - Net profit attributable to shareholders decreased by 8.13% to CNY 45,672,678.44 compared to the same period last year[9] - Net profit attributable to shareholders after deducting non-recurring gains and losses increased by 32.29% to CNY 41,120,894.81[9] - The company reported a total net profit of CNY 137,763,777.33 for the year-to-date, reflecting a 22.99% increase compared to the previous year[9] - The basic earnings per share for the period was CNY 0.1142, a decrease of 8.13%[9] - The total comprehensive income for the current period was ¥44,018,288.48, compared to ¥49,406,904.56 in the previous period, indicating a decline of 10.5%[74] - The net profit for the current period is CNY 137,763,777.33, an increase of 22.9% compared to CNY 112,015,559.81 from the previous period[80] - The total profit for the current period is CNY 162,299,685.34, up from CNY 132,254,812.52, reflecting a growth of 22.7%[80] Assets and Liabilities - Total assets increased by 43.61% to CNY 1,570,576,726.13 compared to the end of the previous year[9] - The company reported a total asset of CNY 1,093,630,023.08 as of September 30, 2019[114] - Total liabilities as of September 30, 2019, were ¥534,587,187.91, which is a significant increase from ¥264,715,973.11 on December 31, 2018, marking a growth of 102.1%[46] - The total liabilities rose to ¥514,182,550.18, up from ¥250,034,343.29 in the previous period, indicating a growth of 105.7%[59] - The company's equity attributable to shareholders reached CNY 828,914,049.97[115] - The company's equity increased to ¥1,039,062,972.97, compared to ¥832,699,849.18 in the previous period, representing a growth of 25%[59] Cash Flow - Net cash flow from operating activities surged by 196.62% to CNY 49,867,706.70[9] - The net cash flow from operating activities decreased by 54.67% to ¥21,906,668.59, attributed to increased payments related to the construction of the new GMP production base[27] - The total cash inflow from financing activities reached ¥312,129,516.00, a substantial increase of 540.92%, primarily due to funds raised from convertible bonds and restricted stock subscriptions[27] - The cash and cash equivalents net increase was ¥34,802,141.87, down 82.79% compared to the previous year, mainly due to reduced cash income from the maturity of acceptance bills[27] - Operating cash inflow totaled ¥487,659,408.23, slightly up from ¥482,817,702.61 in the previous period[96] - Financing cash inflow was ¥312,129,516.00, a notable increase from ¥48,700,000.00 in the previous period[99] Inventory and Receivables - The company reported a significant increase in inventory, rising by 36.90% to 77,158,280.36 RMB due to expanded sales scale and increased stocking[21] - Other receivables increased by 75.60% to 10,938,675.95 RMB, attributed to the expansion of business operations[21] - Accounts receivable increased to ¥243,660,237.78 from ¥207,115,907.30, representing an increase of 17.6%[40] - The company adjusted accounts receivable by CNY -30,375,129.79, reallocating this amount to financing receivables[115] Research and Development - R&D expenses rose to ¥15,745,612.75, marking a significant increase of 76.91% year-over-year, primarily due to increased investment in research and development[25] - Research and development expenses for the current period were ¥6,403,267.41, significantly higher than ¥2,825,468.50 in the previous period, marking an increase of 126.5%[60] - Research and development expenses increased to CNY 16,352,755.60, compared to CNY 8,900,346.52 in the previous period, marking an increase of 83.5%[88] Financial Management - The company has not reported any overdue or unrecoverable amounts related to entrusted financial management, indicating a stable financial management strategy[35] - The company began implementing new financial instrument standards, leading to a reclassification of receivables and a significant decrease in notes receivable by 98.06%[21] - The company implemented new financial instrument standards starting January 1, 2019, affecting the classification of certain financial assets[124] Shareholder Information - The top ten shareholders held a combined 86.10% of the shares, with the largest shareholder owning 46.84%[13] - The company's undistributed profits increased to ¥403,717,921.97, a rise of 44.21% compared to the previous year, driven by expanding market size and rising sales volume[25]